Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation Protocol

The combined analysis of circulating cell-free (tumor) DNA (cfDNA/ctDNA) and circulating cell-free (tumor) RNA (cfRNA/ctRNA) shows great promise in determining the molecular profile of cancer patients. Optimization of the workflow is necessary to achieve consistent and reproducible results. In this study, we compared five centrifugation protocols for the optimal yield of both cfDNA/ctDNA and cfRNA/ctRNA. These protocols varied in centrifugation speed, ambient temperature, time, and number of centrifugation steps. Samples from 33 participants were collected in either BD Vacutainer K2EDTA (EDTA) tubes or cell-free DNA BCT® (Streck) tubes. cfDNA concentration and fragment size, and cfRNA concentration were quantitated in all samples by digital droplet PCR (ddPCR) and quantitative PCR (qPCR). The KRAS-mutated ctDNA and ctRNA fraction was determined via ddPCR. In EDTA tubes, the protocol generating both plasma and platelets was found to produce high quality cfDNA and cfRNA concentrations. Two-step, high-speed centrifugation protocols were associated with high cfDNA but low cfRNA concentrations. High cfRNA concentrations were generated by a one-step, low-speed protocol. However, this coincided with a high amount of genomic DNA (gDNA) contamination. In Streck tubes, two-step, high-speed centrifugation protocols also generated good quality, high cfDNA concentration. However, these tubes are not compatible with cfRNA analysis.

[1]  T. V. van Leeuwen,et al.  Centrifugation affects the purity of liquid biopsy‐based tumor biomarkers , 2018, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[2]  N. Rosenfeld,et al.  Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients , 2018, The Journal of molecular diagnostics : JMD.

[3]  N. Normanno,et al.  The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios. , 2018, Cancer treatment reviews.

[4]  J. V. van Meerbeeck,et al.  A Multicenter Study to Assess EGFR Mutational Status in Plasma: Focus on an Optimized Workflow for Liquid Biopsy in a Clinical Setting , 2018, Cancers.

[5]  K. Spindler,et al.  Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing , 2018, Translational oncology.

[6]  N. George.  Abstract 4586: Evaluation of available blood collection tubes for use in stabilizing concentrations of extracellular vesicles / exosomes and associated cell-free RNA , 2018, Clinical Research (Excluding Clinical Trials).

[7]  T. Wurdinger,et al.  Tumor-Educated Platelets as a Noninvasive Biomarker Source for Cancer Detection and Progression Monitoring. , 2018, Cancer research.

[8]  M. Berger,et al.  The value of cell‐free DNA for molecular pathology , 2018, The Journal of pathology.

[9]  P. Schirmacher,et al.  A field guide for cancer diagnostics using cell‐free DNA: From principles to practice and clinical applications , 2018, Genes, chromosomes & cancer.

[10]  P. Pauwels,et al.  Tumorbank@uza: A Collection of Tissue, Fluid Samples and Associated Data of Oncology Patients for the Use in Translational Research , 2018 .

[11]  M. Huibers,et al.  Preanalytical blood sample workup for cell‐free DNA analysis using Droplet Digital PCR for future molecular cancer diagnostics , 2017, Cancer medicine.

[12]  M. Cowley,et al.  Evaluation of Streck BCT and PAXgene Stabilised Blood Collection Tubes for Cell-Free Circulating DNA Studies in Plasma , 2017, Molecular Diagnosis & Therapy.

[13]  James D. Brenton,et al.  Liquid biopsies come of age: towards implementation of circulating tumour DNA , 2017, Nature Reviews Cancer.

[14]  A. Bardelli,et al.  Integrating liquid biopsies into the management of cancer , 2017, Nature Reviews Clinical Oncology.

[15]  Stefan Sleijfer,et al.  Application of circulating tumor DNA in prospective clinical oncology trials – standardization of preanalytical conditions , 2017, Molecular oncology.

[16]  A. Shaw,et al.  Targeting ALK: Precision Medicine Takes on Drug Resistance. , 2017, Cancer discovery.

[17]  A. Sapa,et al.  An efficient method for isolation of representative and contamination-free population of blood platelets for proteomic studies , 2017, Platelets.

[18]  J. Vandesompele,et al.  The extracellular RNA quality control (exRNAQC) study : testing and controlling pre-analytical variables of RNA sequencing on liquid biopsies , 2017 .

[19]  P. Pauwels,et al.  A Comparison of Cell-Free DNA Isolation Kits: Isolation and Quantification of Cell-Free DNA in Plasma. , 2017, The Journal of molecular diagnostics : JMD.

[20]  F. Diehl,et al.  Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing , 2016, PloS one.

[21]  Lauren L. Ritterhouse,et al.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer , 2016 .

[22]  A. Quyyumi,et al.  Platelets confound the measurement of extracellular miRNA in archived plasma , 2016, Scientific Reports.

[23]  A. Kohlmann,et al.  Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC) , 2016, PloS one.

[24]  Gang Li,et al.  Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. , 2015, Cancer discovery.

[25]  T. Wurdinger,et al.  Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer , 2015, Oncotarget.

[26]  Dereje D. Jima,et al.  A comprehensive joint analysis of the long and short RNA transcriptomes of human erythrocytes , 2015, BMC Genomics.

[27]  Pieter Wesseling,et al.  RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics , 2015, Cancer cell.

[28]  Alison S. Devonshire,et al.  Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification , 2014, Analytical and Bioanalytical Chemistry.

[29]  T. Williams,et al.  A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR. , 2013, Clinical biochemistry.

[30]  A novel blood collection device stabilizes cell-free RNA in blood during sample shipping and storage , 2013, BMC Research Notes.

[31]  F. Mouliere,et al.  Circulating cell free DNA: Preanalytical considerations. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[32]  E. Kroh,et al.  Plasma Processing Conditions Substantially Influence Circulating microRNA Biomarker Levels , 2013, PloS one.

[33]  J. Qin,et al.  Stabilization of cell-free RNA in blood samples using a new collection device. , 2012, Clinical biochemistry.

[34]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.

[35]  K. Kinzler,et al.  Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. , 2007, Cancer research.

[36]  S. Novaković,et al.  Optimization of an RNA isolation procedure from plasma samples. , 2007, International journal of molecular medicine.

[37]  L. Poon,et al.  Clinical Chemistry 47:9 1607–1613 (2001) Molecular Diagnostics and Genetics Effects of Blood-Processing Protocols on Fetal and Total DNA Quantification in Maternal Plasma , 2001 .